Insight Molecular Diagnostics (IMDX) Operating Income (2015 - 2026)

Insight Molecular Diagnostics has reported Operating Income for 12 years, with the latest figure at -$9.1 million in Q1 2026.

• Quarterly Operating Income fell 33.62% year-over-year to -$9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45.1 million (up 11.02% YoY) and the FY2025 annual result came in at -$51.1 million, up 16.25% from the prior year.
• Operating Income climbed to -$9.1 million in Q1 2026 per IMDX's latest filing, from -$23.4 million in the prior quarter.
• Over five years, Operating Income peaked at $5.8 million in Q1 2023 and troughed at -$33.6 million in Q4 2024.
• A 5-year average of -$8.1 million and a median of -$6.5 million in 2023 frame the typical range for Operating Income.
• The widest YoY moves for Operating Income: up 293.9% in 2023, down 410.09% in 2023.
• Over 5 years, Operating Income stood at -$11.6 million in 2022, then grew by 18.62% to -$9.5 million in 2023, then tumbled by 254.75% to -$33.6 million in 2024, then soared by 30.31% to -$23.4 million in 2025, then jumped by 61.23% to -$9.1 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$9.1 million, -$23.4 million, and -$6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.